These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18833404)

  • 1. Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparative multicenter trial.
    Rubio FG; Cunha CA; Lundgren FL; Lima MP; Teixeira PJ; Oliveira JC; Golin V; Mattos WL; Mählmann HK; Moreira ED; Jardim JR; Silva RL; Silva PH
    Braz J Infect Dis; 2008 Jun; 12(3):202-9. PubMed ID: 18833404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
    Zervos M; Mandell LA; Vrooman PS; Andrews CP; McIvor A; Abdulla RH; de Caprariis PJ; Knirsch CA; Amsden GW; Niederman MS; Lode H
    Treat Respir Med; 2004; 3(5):329-36. PubMed ID: 15606222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
    Frank E; Liu J; Kinasewitz G; Moran GJ; Oross MP; Olson WH; Reichl V; Freitag S; Bahal N; Wiesinger BA; Tennenberg A; Kahn JB
    Clin Ther; 2002 Aug; 24(8):1292-308. PubMed ID: 12240780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
    Todisco T; Dal Farra F; Ciliberti G; Pirina P; Guelfi R; Serra G; Paris R; Mancuso I; Cepparulo M
    J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia.
    Chaudhary M; Ayub SG; Mir MA;
    J Infect Public Health; 2018; 11(5):691-697. PubMed ID: 29803638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
    Kohno S; Tateda K; Kadota J; Fujita J; Niki Y; Watanabe A; Nagashima M
    J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
    Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
    Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
    Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial.
    Rob F; Klubalová B; Nyčová E; Hercogová J; Unemo M
    Clin Microbiol Infect; 2020 Feb; 26(2):207-212. PubMed ID: 31419483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
    Rank DR; Friedland HD; Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia.
    Petermann W; Alegre-Martin J; Odenholt I; Phillips MJ; Willcox PA; Tack K; Trostmann U; Welling L
    Scand J Infect Dis; 2001; 33(11):832-7. PubMed ID: 11760164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
    Vetter N; Cambronero-Hernandez E; Rohlf J; Simon S; Carides A; Oliveria T; Isaacs R;
    Clin Ther; 2002 Nov; 24(11):1770-85. PubMed ID: 12501873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
    Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
    Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
    J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.
    Paris R; Confalonieri M; Dal Negro R; Ligia GP; Mos L; Todisco T; Rastelli V; Perna G; Cepparulo M
    J Chemother; 2008 Feb; 20(1):77-86. PubMed ID: 18343748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.